The present disclosure relates to a drug delivery carrier including: (a) a biocompatible polymer and (b) a hydrophobic group conjugated to the polymer. The drug delivery carrier according to the present disclosure having the hydrophobic group conjugated to the biocompatible polymer may be useful for adsorption of synthetic drugs having very low solubility in water. Further, it may regulate discharge rate of adsorbed drugs by regulating a portion of hydrophobic groups conjugated to the polymeric material. Thus, the present disclosure provides a broad-spectrum platform technology applicable to new hydrophobic synthetic drugs to be developed in the future as well as those that have been developed already but face difficulties due to low bioavailability. The disclosed drug delivery carrier may provide considerable therapeutic convenience for patients by combining stained-release characteristics with the ability for adsorption of a hydrophobic drug having low bioavailability.The drug delivery carrier according to the present disclosure may also be applied to protein therapeutics. For patent-expired first-generation protein drugs requiring daily or once-in-two-or-three-days injection, the present disclosure improves convenience by allowing second-generation injection formulations that are administered once a week or once or twice a month. As used herein, a "first-generation protein drug" refers to a biomedicine based on a natural protein prepared by a gene recombination technique and a "second-generation protein drug" refers to a biopharmaceutical improvement of a first-generation protein drug through formulation or modification of molecular structure for increasing half-life or extending treatment period through sustained release. The present disclosure provides a strong tool capable of achieving the desired effect simply by mixing with or adsorbing to the drug delivery carrier, unlike known techniques requiring modification or introduction of a special molecular structu